Live Breaking News & Updates on Mcl

Stay updated with breaking news from Mcl . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Danilov on Addressing BTK Inhibitor Resistance in Relapsed/Refractory CLL and MCL

Alexey Danilov, MD, PhD, discusses how further research, including the development of NX-2127, may address unmet needs related to disease progression in patients with chronic lymphocytic leukemia or mantle cell lymphoma.

Alexey-danilov , Department-of-hematology-hematopoietic-cell-transplantation , Division-of-leukemia , Toni-stephenson-lymphoma-center , Hematopoietic-cell-transplantation , Ity-of-hope , Mantle-cell-lymphoma , Mcl- , Cll , Chronic-lymphocytic-leukemia , Onclive-tv ,

Dr Cohen on the Efficacy of Pirtobrutinib in High-Risk Patients With MCL

Jonathon B. Cohen, MD, MS, discusses safety and efficacy outcomes with pirtobrutinib in previously treated patients with relapsed/refractory mantle cell lymphoma, as observed in the phase 1/2 BRUIN study.

Jonathonb-cohen , Emory-university-school-of-medicine , Winship-cancer-institute , Safety-monitoring-committee , Department-of-hematology , Lymphoma-program , Medical-oncology , Emory-university-school , Sh-annual-meeting , Onclive-tv , Conference

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Andre-goy , John-theurer-cancer-center , Hackensack-meridian-health-oncology-care-transformation-services , Hackensack-university-medical-center , Lymphoma-division , Ash-annual-meeting-and-exposition , Onclive-tv , Conference- , Mantle-cell-lymphoma , Mcl- , Ash-2023 ,

Acalabrutinib Plus BR Leads to High CR Rates in Treatment-Naive, Relapsed/Refractory MCL

The addition of acalabrutinib to bendamustine and rituximab demonstrated potent and durable responses despite a high incidence of grade 3/4 adverse effects in patients with previously untreated and relapsed/refractory mantle cell lymphoma.

Michigan , United-states , Germany , Tycel-phillips , University-of-michigan-comprehensive-cancer-center , European-hematology-association-congress , Michigan-comprehensive-cancer , Hematology-association-congress , News , Conference , Mcl- , Mantle-cell-lymphoma